Display options
Cite
Jones R, Rickards H, Cavanna AE. Gabapentin enacarbil: pharmacotherapy of restless legs syndrome. J Cent Nerv Syst Dis. 2010;2:45-55doi: 10.4137/JCNSD.S4886.
Jones, R., Rickards, H., & Cavanna, A. E. (2010). Gabapentin enacarbil: pharmacotherapy of restless legs syndrome. Journal of central nervous system disease, 245-55. https://doi.org/10.4137/JCNSD.S4886
Jones, Ruth, et al. "Gabapentin enacarbil: pharmacotherapy of restless legs syndrome." Journal of central nervous system disease vol. 2 (2010): 45-55. doi: https://doi.org/10.4137/JCNSD.S4886
Jones R, Rickards H, Cavanna AE. Gabapentin enacarbil: pharmacotherapy of restless legs syndrome. J Cent Nerv Syst Dis. 2010 Nov 23;2:45-55. doi: 10.4137/JCNSD.S4886. Print 2010. PMID: 23861631; PMCID: PMC3661230.
Copy Download .nbib Format: NLM
Share it on

J Cent Nerv Syst Dis. 2010 Nov 23;2:45-55. doi: 10.4137/JCNSD.S4886. Print 2010.

Gabapentin enacarbil: pharmacotherapy of restless legs syndrome.

Journal of central nervous system disease

Ruth Jones, Hugh Rickards, Andrea Eugenio Cavanna

Affiliations

  1. Department of Neuropsychiatry, BSMHFT and University of Birmingham, Birmingham, UK.

PMID: 23861631 PMCID: PMC3661230 DOI: 10.4137/JCNSD.S4886

Abstract

Restless Legs Syndrome (RLS) is a prevalent sleep-associated movement disorder greatly affecting patients' quality of life (QoL). Several drugs can be used to control this condition although the first-line dopamine agents often cause adverse effects. Non-dopaminergic drugs such as oral gabapentin (GBP) have been more recently advocated. Despite ameliorating RLS symptoms, GBP's pharmacokinetic limitations restrict its overall effectiveness. A novel specifically designed prodrug, gabapentin enacarbil (GE), has demonstrated successful RLS alleviation with a superior pharmacokinetic profile. This review aims to examine the efficacy and tolerability of both GBP and GE as pharmacotherapy for RLS. Despite some heterogeneity and limitations across research methodologies, GE appears to be a potential RLS therapy superior to GBP and other dopaminergic agents.

Keywords: gabapentin; gabapentin enacarbil; pharmacotherapy; restless legs syndrome

References

  1. Neurology. 2001 Nov 13;57(9):1717-9 - PubMed
  2. Mayo Clin Proc. 2010 Jun;85(6):512-21 - PubMed
  3. Neuropsychiatr Dis Treat. 2010 May 06;6:151-8 - PubMed
  4. Am J Kidney Dis. 2001 Jul;38(1):104-8 - PubMed
  5. Clin Ther. 2009 Aug;31(8):1776-86 - PubMed
  6. Clin Neuropharmacol. 2009 Nov-Dec;32(6):311-20 - PubMed
  7. Br J Clin Pharmacol. 2010 May;69(5):498-507 - PubMed
  8. Ren Fail. 2004 Jul;26(4):393-7 - PubMed
  9. J Pharmacol Exp Ther. 2004 Oct;311(1):315-23 - PubMed
  10. Neurology. 2002 Nov 26;59(10):1573-9 - PubMed
  11. Sleep. 2009 Feb;32(2):159-68 - PubMed
  12. Ther Adv Neurol Disord. 2010 Sep;3(5):269-75 - PubMed
  13. Neurology. 2009 Feb 3;72(5):439-46 - PubMed
  14. Clin Neuropharmacol. 1997 Apr;20(2):148-51 - PubMed
  15. Sleep. 1996 Apr;19(3):205-13 - PubMed
  16. Expert Opin Pharmacother. 2010 Aug;11(11):1925-32 - PubMed
  17. Neuropsychobiology. 2003;48(2):82-6 - PubMed
  18. J Clin Pharmacol. 2008 Dec;48(12):1378-88 - PubMed

Publication Types